Clinical and parasitological studies on the efficacy of Mirazid in treatment of schistosomiasis haematobium in Tatoon, Etsa Center, El Fayoum Governorate.

No doubt, schistosomiasis tops all the endemic parasitic diseases world-wide particularly in Egypt. This study evaluated the efficacy of Mirazid (Commiphora molmol) in the treatment of parasitologically and clinically and ultrasonography confirmed cases of schistosomiasis haematobium in Tatoon village. A sum of 70 out of 885 individuals of both sexes (>15 to 60 years old) screened for S. haematobium infection were selected. They had light infection (1-10 eggs/10 ml.), moderate infection (10-100 eggs/10 ml.) and heavy infection (>100/10 ml.). They were subjected to urine and stool analysis, renal function tests, clinical examination and abdomino-pelvic ultrasound. They were treated with Mirazid as 10 mgm/Kg. However, eight of them were unable to swallow the drug. Out of the 62 schistosomiasis haematobium patients, 57 (91.9%) were cured after two months follow up and the cure rate reached 59 (95.2%) on the 3rd month post-Mirazid treatment. The cure result was evaluated clinically, parasitologically and ultrasonographically. So, Mirazid in a dose of two capsules (600 mgm) on an empty stomach before breakfast for six successive days proved to be very effective and safe in the treatment of schistosomiasis haematobium.